LONDON, UK

View Full Event Program

View the full event program for Precision CRISPR Drug Discovery & Gene Therapy Europe 2018 with detailed agenda, workshop details, expert speaker line-up, 18+ focused case studies and attendance breakdown.

Capture

AGENDA HIGHLIGHTS

Take a look at the agenda highlights below. To view all 18 case-studies, roundtable sessions and workshop details view full event program.

CASE STUDY: Gene Repair in Human Hematopoietic Stem Cells

  • A systematic approach for generating knock-ins in stem cells
  • Identifying and improving the precision of HDR events
  • Use of live imaging and gene editing to explore cell states

Jacob Corn
Professor of Genome Biology
ETH Zurich

Take a look at Jacob Corn's presentation at the TEDxBerkeley
The end of genetic disease

Tony Perry

“A genome Editing Switch” Session with Dr Tony Perry of the University of Bath will touch on the following areas:

  • How genetic code expansion works in mammalian cells
  • Switching on Cas9 activity with a non-physiological amino acid, BOC
  • Examples of heritable, BOC-induced genome editing
  • Some potential applications

Dr Tony Perry
Head of the Laboratory of Mammalian Molecular Embryology
University of Bath

Take a look at Tony Perry's presentation at the TEDxThessaloniki
Are we ready for heritable genome editing to change our lives?

CASE STUDY: Utilising CRISPR Screen in Difficult Cells, Studies of Primary Immune Cells

Fredrik Wermeling
Assistant professor
Karolinska Institue

CASE STUDY: Mouse Genome Editing Using CRISPR/Cas9 Technology

  • Different forms of Cas9 and gRNA used for genome editing
  • Targeted gene disruption and deletion to generate gene KO mice
  • Site-specific transgene integration to generate gene KI mice

Lin Wu
Director
Genome Modification Facility at Harvard University

CASE STUDY: Detection of in vitro and ex vivo Cellular indel Profiles and Dynamics Induced By Different CRISPR/Cas9 Delivery Formats

  • Methodologies for absolute identification of cellular Cas9 induced indel events
  • Plasmid-, piggyback-, lenti- and RNP -Cas9 delivery formats
  • Indel formation dynamics and profiles induced by various CRISPR/Cas9 delivery methods
  • In vitro and ex vivo Indel formation, dynamics and profiles induced by various CRISPR/ Cas9 delivery formats

Eric Paul Bennet
Associate professor
University of Copenhagen

CASE STUDY: Modelling neurodegenerative disease using isogenic pairs of human iPSCs generated by CRISPR/Cas9

  • Efficient production of isogenic iPSC lines using CRISPR RNP and high throughput
    sequencing
  • Use of isogenic cell pairs to understand the causative genetic aberrations, independent
    of genetic background
  • Identification of perturbed cellular stress responses in an iPSC-derived model of Parkinson’s disease (alpha-synuclein triplication)

Andrew Bassett
Head of Research
(Cellular Operations)

Wellcome Trust Sanger Institute

CASE STUDY: Precise Genome Engineering to Empower Drug Discovery

  • Pooled and arrayed CRIPSR screening for Target Identification
  • Target Validation in CRISPR enabled cell and animal models of disease
  • Precision medicine approaches in Oncology and beyond

Barry Rosen
VP & & Senior Principal Scientist
Astra Zeneca